Safety and Efficacy of Low Dose CD19 Targeted Chimeric Antigen Receptor T (CAR-T) Cell Immunotherapy in 47 Cases with Relapsed Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL)

被引：6
|
作者：
Deng, Biping [1 ]
Chang, Alex Hongsheng [2 ]
Yang, Junfang [3 ]
Pan, Jing [3 ]
Zhang, Xian [3 ]
Lin, Yuehui [3 ]
Wu, Yanan [1 ]
Deng, Zhenling [1 ]
Lu, Peihua [3 ]
Wu, Tong [4 ]
Liu, Zhaoli [1 ]
Zhang, Yu'e [1 ]
Tong, Chunrong [3 ]
机构：
[1] Hebei Yanda Lu Daopei Hosp, Immunotherapy Dept, Langfang, Peoples R China
[2] Tongji Univ, Sch Med, Shanghai, Peoples R China
[3] Hebei Yanda Lu Daopei Hosp, Hematopathol, Langfang, Peoples R China
[4] Hebei Yanda Lu Daopei Hosp, Bone Marrow Transplantat, Langfang, Peoples R China
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.649.649
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
649
引用
收藏
页数：7
相关论文
共 50 条
  • [1] CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS TARGETING THE CD19 ANTIGEN FOR THE TREATMENT OF RELAPSED B CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
    Curran, Kevin
    PEDIATRIC BLOOD & CANCER, 2014, 61 : S6 - S6
  • [2] CD19 CAR-T Cell Therapy in Children with Relapsed and Refractory B-ALL
    Molostova, Olga
    Shelikhova, Larisa
    Muzalevsky, Yakov
    Kazachenok, Alexey
    Khismatullina, Rimma
    Abugova, Julia
    Kurnikova, Elena
    Trakhtman, Pavel
    Pershin, Dmitry
    Zubachenko, Viktoria
    Fadeeva, Maria
    Popov, Alexander M.
    Illarionova, Olga
    Miakova, Natalia
    Litvinov, Dmitry
    Novichkova, Galina
    Maschan, Alexey
    Maschan, Michael
    BLOOD, 2021, 138
  • [3] Efficacy of CD19-targeted chimeric antigen receptor T cells in the treatment of relapsed extramedullary B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL).
    Hu, Yongxian
    Wu, Zhao
    Yu, Jian
    Wang, Jiasheng
    Wei, Guoqing
    Wu, Wenjun
    Luo, Yi
    Shi, Jimin
    Xiao, Lei
    Huang, He
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia
    Zhou, Qianyi
    An, Yuxin
    Zhang, Xiaomei
    Xiao, Xia
    Bai, Xue
    Liu, Pengjiang
    Pu, Yedi
    Meng, Juanxia
    Zhu, Haibo
    Lyu, Cuicui
    Zhang, Huan
    Zhang, Yu
    Xie, Tianle
    Meng, Haotian
    Lyu, Hairong
    FRONTIERS IN IMMUNOLOGY, 2025, 16
  • [5] Efficacy and Safety of the Second CAR-T Therapy in Patients with Refractory/Relapsed Acute B-Cell Lymphoblastic Leukemia
    Liu, Sining
    Cui, Qingya
    Li, Zheng
    Cui, Wei
    Li, Mengyun
    Qiu, Huiying
    Xue, Shengli
    Chen, Suning
    Jin, Zhengming
    Miao, Miao
    Han, Yue
    Wang, Ying
    Zhu, Xiaming
    Yu, Lei
    Wu, Depei
    Tang, Xiaowen
    BLOOD, 2023, 142
  • [6] Prominent efficacy and good safety of sequential CD19 and CD22 CAR-T therapy in relapsed/refractory adult B-cell acute lymphoblastic leukemia
    Yang, Tingting
    Dong, Yetian
    Zhang, Mingming
    Feng, Jingjing
    Fu, Shan
    Xiao, Pingnan
    Hong, Ruimin
    Xu, Huijun
    Cui, Jiazhen
    Huang, Simao
    Wei, Guoqing
    Kong, Delin
    Geng, Jia
    Chang, Alex H.
    Huang, He
    Hu, Yongxian
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2025, 14 (01)
  • [7] Safety and efficacy of a humanized CD19 chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic leukemia
    Shi, Ming
    Li, Li
    Wang, Shiyuan
    Cheng, Hai
    Chen, Wei
    Sang, Wei
    Qi, Kunming
    Li, Zhenyu
    Wang, Gang
    Li, Huizhong
    Lan, Jianping
    Huang, Jinqi
    Fei, Xiaoming
    Yu, Min
    Li, Fei
    Qiao, Jianlin
    Wu, Qingyun
    Zeng, Lingyu
    Jing, Guangjun
    Zheng, Junnian
    Gale, Robert Peter
    Xu, Kailin
    Cao, Jiang
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (06) : 711 - 718
  • [8] Chimeric Antigen Receptor T-Cell Therapy (CAR-T) in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL): A Systematic Review and Meta-Analysis
    Grover, Punita
    Veilleux, Olivier
    Tian, Lu
    Sun, Ryan
    Previtera, Melissa
    Curran, Emily
    Muffly, Lori
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S454 - S454
  • [9] CD19-Targeted CAR T Cells as Novel Cancer Immunotherapy for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
    Davila, Marco L.
    Brentjens, Renier J.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (10) : 802 - 808
  • [10] Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia
    Gu, Runxia
    Liu, Fang
    Zou, Dehui
    Xu, Yingxi
    Lu, Yang
    Liu, Bingcheng
    Liu, Wei
    Chen, Xiaojuan
    Liu, Kaiqi
    Guo, Ye
    Gong, Xiaoyuan
    Lv, Rui
    Chen, Xia
    Zhou, Chunlin
    Zhong, Mengjun
    Wang, Huijun
    Wei, Hui
    Mi, Yingchang
    Qiu, Lugui
    Lv, Lulu
    Wang, Min
    Wang, Ying
    Zhu, Xiaofan
    Wang, Jianxiang
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
12345